DrugPatentWatch Database Preview
Email this page to a colleague» See Plans and Pricing
« Back to Dashboard
The generic ingredient in MULPLETA is lusutrombopag. One supplier is listed for this compound. Additional details are available on the lusutrombopag profile page.
Generic Entry Opportunity Date for 210923
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Suppliers and Packaging for NDA: 210923
Profile for product number 001
|Approval Date:||Jul 31, 2018||TE:||RLD:||Yes|
|Regulatory Exclusivity Expiration:||Jul 31, 2023|
|Regulatory Exclusivity Use:||NEW CHEMICAL ENTITY|
|Patent:||Start Trial||Patent Expiration:||Sep 5, 2024||Product Flag?||Y||Substance Flag?||Y||Delist Request?|
|Patented Use:||TREATMENT OF THROMBOCYTOPENIA IN ADULT PATIENTS WITH CHRONIC LIVER DISEASE WHO ARE SCHEDULED TO UNDERGO A PROCEDURE|
|Patent:||Start Trial||Patent Expiration:||Jan 21, 2030||Product Flag?||Y||Substance Flag?||Y||Delist Request?|
Complete Access Available with Subscription